Global Gene Therapy for Age-related Macular Degeneration Market Research Report 2023

Report ID: 1988903 | Published Date: Jan 2025 | No. of Page: 61 | Base Year: 2024 | Rating: 5 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
        1.2.2 Subretinal
        1.2.3 Intravitreal
    1.3 Market by Application
        1.3.1 Global Gene Therapy for Age-related Macular Degeneration Market Share by Application: 2017 VS 2021 VS 2028
        1.3.2 Monotherapy
        1.3.3 Combination Therapy
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Gene Therapy for Age-related Macular Degeneration Market Perspective (2017-2028)
    2.2 Gene Therapy for Age-related Macular Degeneration Growth Trends by Region
        2.2.1 Gene Therapy for Age-related Macular Degeneration Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Gene Therapy for Age-related Macular Degeneration Historic Market Size by Region (2017-2022)
        2.2.3 Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Region (2023-2028)
    2.3 Gene Therapy for Age-related Macular Degeneration Market Dynamics
        2.3.1 Gene Therapy for Age-related Macular Degeneration Industry Trends
        2.3.2 Gene Therapy for Age-related Macular Degeneration Market Drivers
        2.3.3 Gene Therapy for Age-related Macular Degeneration Market Challenges
        2.3.4 Gene Therapy for Age-related Macular Degeneration Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Gene Therapy for Age-related Macular Degeneration Players by Revenue
        3.1.1 Global Top Gene Therapy for Age-related Macular Degeneration Players by Revenue (2017-2022)
        3.1.2 Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Players (2017-2022)
    3.2 Global Gene Therapy for Age-related Macular Degeneration Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Gene Therapy for Age-related Macular Degeneration Revenue
    3.4 Global Gene Therapy for Age-related Macular Degeneration Market Concentration Ratio
        3.4.1 Global Gene Therapy for Age-related Macular Degeneration Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Gene Therapy for Age-related Macular Degeneration Revenue in 2021
    3.5 Gene Therapy for Age-related Macular Degeneration Key Players Head office and Area Served
    3.6 Key Players Gene Therapy for Age-related Macular Degeneration Product Solution and Service
    3.7 Date of Enter into Gene Therapy for Age-related Macular Degeneration Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Gene Therapy for Age-related Macular Degeneration Breakdown Data by Type
    4.1 Global Gene Therapy for Age-related Macular Degeneration Historic Market Size by Type (2017-2022)
    4.2 Global Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Type (2023-2028)
5 Gene Therapy for Age-related Macular Degeneration Breakdown Data by Application
    5.1 Global Gene Therapy for Age-related Macular Degeneration Historic Market Size by Application (2017-2022)
    5.2 Global Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Gene Therapy for Age-related Macular Degeneration Market Size (2017-2028)
    6.2 North America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2017-2022)
    6.3 North America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2023-2028)
    6.4 United States
    6.5 Canada
7 Europe
    7.1 Europe Gene Therapy for Age-related Macular Degeneration Market Size (2017-2028)
    7.2 Europe Gene Therapy for Age-related Macular Degeneration Market Size by Country (2017-2022)
    7.3 Europe Gene Therapy for Age-related Macular Degeneration Market Size by Country (2023-2028)
    7.4 Germany
    7.5 France
    7.6 U.K.
    7.7 Italy
    7.8 Russia
    7.9 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size (2017-2028)
    8.2 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Country (2017-2022)
    8.3 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Country (2023-2028)
    8.4 China
    8.5 Japan
    8.6 South Korea
    8.7 Southeast Asia
    8.8 India
    8.9 Australia
9 Latin America
    9.1 Latin America Gene Therapy for Age-related Macular Degeneration Market Size (2017-2028)
    9.2 Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2017-2022)
    9.3 Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2023-2028)
    9.4 Mexico
    9.5 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size (2017-2028)
    10.2 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Country (2017-2022)
    10.3 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Country (2023-2028)
    10.4 Turkey
    10.5 Saudi Arabia
    10.6 UAE
11 Key Players Profiles
    11.1 RetroSense Therapeutics
        11.1.1 RetroSense Therapeutics Company Detail
        11.1.2 RetroSense Therapeutics Business Overview
        11.1.3 RetroSense Therapeutics Gene Therapy for Age-related Macular Degeneration Introduction
        11.1.4 RetroSense Therapeutics Revenue in Gene Therapy for Age-related Macular Degeneration Business (2017-2022)
        11.1.5 RetroSense Therapeutics Recent Development
    11.2 REGENXBIO
        11.2.1 REGENXBIO Company Detail
        11.2.2 REGENXBIO Business Overview
        11.2.3 REGENXBIO Gene Therapy for Age-related Macular Degeneration Introduction
        11.2.4 REGENXBIO Revenue in Gene Therapy for Age-related Macular Degeneration Business (2017-2022)
        11.2.5 REGENXBIO Recent Development
    11.3 AGTC
        11.3.1 AGTC Company Detail
        11.3.2 AGTC Business Overview
        11.3.3 AGTC Gene Therapy for Age-related Macular Degeneration Introduction
        11.3.4 AGTC Revenue in Gene Therapy for Age-related Macular Degeneration Business (2017-2022)
        11.3.5 AGTC Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details

List of Tables
    Table 1. Global Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
    Table 2. Key Players of Subretinal
    Table 3. Key Players of Intravitreal
    Table 4. Global Gene Therapy for Age-related Macular Degeneration Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
    Table 5. Global Gene Therapy for Age-related Macular Degeneration Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 6. Global Gene Therapy for Age-related Macular Degeneration Market Size by Region (2017-2022) & (US$ Million)
    Table 7. Global Gene Therapy for Age-related Macular Degeneration Market Share by Region (2017-2022)
    Table 8. Global Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 9. Global Gene Therapy for Age-related Macular Degeneration Market Share by Region (2023-2028)
    Table 10. Gene Therapy for Age-related Macular Degeneration Market Trends
    Table 11. Gene Therapy for Age-related Macular Degeneration Market Drivers
    Table 12. Gene Therapy for Age-related Macular Degeneration Market Challenges
    Table 13. Gene Therapy for Age-related Macular Degeneration Market Restraints
    Table 14. Global Gene Therapy for Age-related Macular Degeneration Revenue by Players (2017-2022) & (US$ Million)
    Table 15. Global Gene Therapy for Age-related Macular Degeneration Market Share by Players (2017-2022)
    Table 16. Global Top Gene Therapy for Age-related Macular Degeneration Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapy for Age-related Macular Degeneration as of 2021)
    Table 17. Ranking of Global Top Gene Therapy for Age-related Macular Degeneration Companies by Revenue (US$ Million) in 2021
    Table 18. Global 5 Largest Players Market Share by Gene Therapy for Age-related Macular Degeneration Revenue (CR5 and HHI) & (2017-2022)
    Table 19. Key Players Headquarters and Area Served
    Table 20. Key Players Gene Therapy for Age-related Macular Degeneration Product Solution and Service
    Table 21. Date of Enter into Gene Therapy for Age-related Macular Degeneration Market
    Table 22. Mergers & Acquisitions, Expansion Plans
    Table 23. Global Gene Therapy for Age-related Macular Degeneration Market Size by Type (2017-2022) & (US$ Million)
    Table 24. Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Type (2017-2022)
    Table 25. Global Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 26. Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Type (2023-2028)
    Table 27. Global Gene Therapy for Age-related Macular Degeneration Market Size by Application (2017-2022) & (US$ Million)
    Table 28. Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Application (2017-2022)
    Table 29. Global Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 30. Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Application (2023-2028)
    Table 31. North America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2017-2022) & (US$ Million)
    Table 32. North America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2023-2028) & (US$ Million)
    Table 33. Europe Gene Therapy for Age-related Macular Degeneration Market Size by Country (2017-2022) & (US$ Million)
    Table 34. Europe Gene Therapy for Age-related Macular Degeneration Market Size by Country (2023-2028) & (US$ Million)
    Table 35. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Region (2017-2022) & (US$ Million)
    Table 36. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Region (2023-2028) & (US$ Million)
    Table 37. Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2017-2022) & (US$ Million)
    Table 38. Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2023-2028) & (US$ Million)
    Table 39. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Country (2017-2022) & (US$ Million)
    Table 40. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Country (2023-2028) & (US$ Million)
    Table 41. RetroSense Therapeutics Company Detail
    Table 42. RetroSense Therapeutics Business Overview
    Table 43. RetroSense Therapeutics Gene Therapy for Age-related Macular Degeneration Product
    Table 44. RetroSense Therapeutics Revenue in Gene Therapy for Age-related Macular Degeneration Business (2017-2022) & (US$ Million)
    Table 45. RetroSense Therapeutics Recent Development
    Table 46. REGENXBIO Company Detail
    Table 47. REGENXBIO Business Overview
    Table 48. REGENXBIO Gene Therapy for Age-related Macular Degeneration Product
    Table 49. REGENXBIO Revenue in Gene Therapy for Age-related Macular Degeneration Business (2017-2022) & (US$ Million)
    Table 50. REGENXBIO Recent Development
    Table 51. AGTC Company Detail
    Table 52. AGTC Business Overview
    Table 53. AGTC Gene Therapy for Age-related Macular Degeneration Product
    Table 54. AGTC Revenue in Gene Therapy for Age-related Macular Degeneration Business (2017-2022) & (US$ Million)
    Table 55. AGTC Recent Development
    Table 56. Research Programs/Design for This Report
    Table 57. Key Data Information from Secondary Sources
    Table 58. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Gene Therapy for Age-related Macular Degeneration Market Share by Type: 2021 VS 2028
    Figure 2. Subretinal Features
    Figure 3. Intravitreal Features
    Figure 4. Global Gene Therapy for Age-related Macular Degeneration Market Share by Application in 2021 & 2028
    Figure 5. Monotherapy Case Studies
    Figure 6. Combination Therapy Case Studies
    Figure 7. Gene Therapy for Age-related Macular Degeneration Report Years Considered
    Figure 8. Global Gene Therapy for Age-related Macular Degeneration Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 9. Global Gene Therapy for Age-related Macular Degeneration Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 10. Global Gene Therapy for Age-related Macular Degeneration Market Share by Region: 2021 VS 2028
    Figure 11. Global Gene Therapy for Age-related Macular Degeneration Market Share by Players in 2021
    Figure 12. Global Top Gene Therapy for Age-related Macular Degeneration Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapy for Age-related Macular Degeneration as of 2021)
    Figure 13. The Top 10 and 5 Players Market Share by Gene Therapy for Age-related Macular Degeneration Revenue in 2021
    Figure 14. North America Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 15. North America Gene Therapy for Age-related Macular Degeneration Market Share by Country (2017-2028)
    Figure 16. United States Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 17. Canada Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 18. Europe Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 19. Europe Gene Therapy for Age-related Macular Degeneration Market Share by Country (2017-2028)
    Figure 20. Germany Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 21. France Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 22. U.K. Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 23. Italy Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 24. Russia Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 25. Nordic Countries Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 26. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 27. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Share by Region (2017-2028)
    Figure 28. China Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 29. Japan Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 30. South Korea Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. Southeast Asia Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. India Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. Australia Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 34. Latin America Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 35. Latin America Gene Therapy for Age-related Macular Degeneration Market Share by Country (2017-2028)
    Figure 36. Mexico Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 37. Brazil Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 38. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 39. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Share by Country (2017-2028)
    Figure 40. Turkey Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 41. Saudi Arabia Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 42. RetroSense Therapeutics Revenue Growth Rate in Gene Therapy for Age-related Macular Degeneration Business (2017-2022)
    Figure 43. REGENXBIO Revenue Growth Rate in Gene Therapy for Age-related Macular Degeneration Business (2017-2022)
    Figure 44. AGTC Revenue Growth Rate in Gene Therapy for Age-related Macular Degeneration Business (2017-2022)
    Figure 45. Bottom-up and Top-down Approaches for This Report
    Figure 46. Data Triangulation
    Figure 47. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
RetroSense Therapeutics
REGENXBIO
AGTC
Frequently Asked Questions
Gene Therapy for Age-related Macular Degeneration report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Gene Therapy for Age-related Macular Degeneration report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Gene Therapy for Age-related Macular Degeneration report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports